Modality
siRNA
MOA
IL-13i
Target
RET
Pathway
T-cell
NSCLCRBLN
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
Sep 2020
→ Jun 2029
Phase 1Current
NCT05237230
1,541 pts·LN
2020-09→2029-06·Terminated
1,541 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-253.2y awayInterim· LN
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Termina…
Catalysts
Interim
2029-06-25 · 3.2y away
LN
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05237230 | Phase 1 | LN | Terminated | 1541 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-5389 | Roche | Preclinical | RET | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |